The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

Studies designed, executed, and funded by an Alkermes company.

Filter Publications
Therapeutic Area:
Publication Type:
Showing 3 of 103 results
Sort by date: Ascending
Jul 2025
Healthcare Resource Utilization 6 Months Before and After Olanzapine/Samidorphan Initiation: Real-World Assessment of Patients with Schizophrenia or Bipolar I Disorder
Advances in Therapy
AUTHOR(S)
Cutler AJ, Panchmatia HR, Hughes AG, Webb NS, Doane MJ, Jain R
Aug 2025
Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia
Neuropsychiatric Disease and Treatment
AUTHOR(S)

Weiden PJ, Strand LN, Doane MJ, Arevalo C, McGrory JA, Achtyes ED, Harvey PD, Kane JM, Saklad SR, Trotter J, Velligan DI

Mar 2026
The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)

McIntyre RS, Matthews DM, Arevalo C, McDonnell D, Correll CU